Biotech Pharmaceutical Co., Ltd.
Clinical trials sponsored by Biotech Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody EB070 begins first human safety trial Results expected Dec 2026 (estimated)
-
Can a Lab-Made antibody quiet the immune attack behind Sjögren's syndrome?
Disease control Not yet recruitingResearchers are testing an experimental antibody called JH013 in adults with primary Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands and other tissues. The trial has two parts: one gives a single injection at increasing doses, and the oth…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug JY016 targets EGFR-Positive cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called JY016 in people with advanced solid tumors that have a protein called EGFR. The goal is to find a safe dose and see if the drug can shrink tumors. The trial includes people with several cancer types, such as pancreatic, lung, and colorectal canc…
Phase 1/2 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New antibody EB070 begins first human safety trial
Knowledge-focused Not yet recruitingThis early-stage trial tests the safety of a new drug called EB070, an antibody that blocks a protein involved in allergic inflammation. Thirty-six healthy adults will receive a single injection of either EB070 or a placebo at increasing doses. The study monitors side effects and…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC